Hepatology Topic Homepage

Learning Zones

,Cystic Fibrosis Knowledge Centre

Cystic fibrosis (CF) is a genetic condition caused by a defect in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. In people with CF, the protein does not work effectively, resulting in thick, sticky secretions at epithelial membranes – the underlying defect in CF.1 Cystic fibrosis can have multi-organ involvement with a range of complications and comorbidities reported.

The aim of the Cystic Fibrosis Knowledge Centre is to provide healthcare professionals with accurate clinical information including disease awareness information, emerging and established treatment options and current best practice based on recently updated guidelines by the European Cystic Fibrosis Society (ECFS). A resources section contains external links to upcoming medical conferences and patient support groups.

This resource is developed by EPG Health Media for epgonline.org, supported by an independent educational grant from Vertex.

References:
1. Boucher RC. Cystic Fibrosis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL et al., editors. Harrison's Internal Medicine. 16th ed. New York: McGraw-Hill; 2005. p. 1-9.​

Latest News

Medical Videos

Discussion of Hepatitis C in the UK House of Lords June 2011
Discussion of Hepatitis C in the UK House of Lords June 2011
An Animation of The Hepatitis C Virus and How it Affects the Body
An Animation of The Hepatitis C Virus and How it Affects the Body

Recent Drug Updates

Medical Journal Abstracts on Hepatology

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Fri 29 Jan 2016 -  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT). Untreated ...

Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.

Thu 21 Jan 2016 -  Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.

Background: The duration of protection in children and adults resulting from hepatitis B vaccination is unknown. In 1981, we immunized a cohort of 1578 Alaska Native adults and children from 15 ...

Clinical Guidelines

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

Apr 2015

These Clinical Practice Guidelines (CPGs) have been developed by a panel of experts chosen by the..

... EASL and ALEH Governing Boards. The recommendations were peer-reviewed by external expert reviewers and approved by EASL and ALEH Governing Boards.

EASL Recommendations on Treatment of Hepatitis C 2015

Apr 2015

These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and..

... other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the current optimal management of patients with acute and chronic HCV infections. These recommendations apply to therapies that have been approved in the European Union at the time of their publication.

Online CME

Abnormal liver function tests: a guide to interpretation

After completing this module, you should be able to: interpret abnormal liver function tests, evaluate a patient with abnormal liver function tests, and diagnose the most likely cause of abnormal...

Abnormal liver function tests: pitfalls in diagnosis

After completing this module, you should: be aware that patients who are symptomatic often have a completely different pattern of change to their liver function tests to those who are...

Alcohol related liver disease

After completing this module you should be able to: recognise different patterns of abnormal liver function tests associated with alcoholic liver disease, assess the severity of alcoholic liver disease from...

Clinical Trials

Association Between Autologous Transfusion and Recurrence Among Patients With HCC After Resection (AT/HCC)

Fri 01 Jan 2016

This prospective study aims to determine whether autotransfusion of red blood cells salvaged during liver resection is associated with the recurrence of hepatocellular ...

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes (EmLiFa)

Tue 01 Dec 2015

The effects of empagliflozin treatment on hepatocellular lipid content, liver energy metabolism and body composition will be investigated in a multicentre, prospective, placebo-controlled, ...

Back to top